Argenica Therapeutics Ltd (AU:AGN) has released an update.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Argenica Therapeutics is making significant progress in its Phase 2 trial for acute ischaemic stroke, having dosed 80% of its target patients. The trial, which is on track to complete by mid-2025, is showing positive feedback with no reported issues. Argenica is also preparing to submit an Investigational New Drug application to the FDA, paving the way for future trials in the U.S.
For further insights into AU:AGN stock, check out TipRanks’ Stock Analysis page.